Guy Rodrigue Takoudjou Dzomo

Dr. Guy Rodrigue Takoudjou Dzomo

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2019 in Expert Review of Vaccines
Verified
Journal Article
Closed access
FMFranck J.D. Mennechet
Franck J.D. Mennechet
OPOcéane Paris
Océane Paris
AOAline Raissa Ouoba
Aline Raissa Ouoba
SASofia Salazar Arenas
Sofia Salazar Arenas
SSSodiomon B. Sirima
Sodiomon B. Sirima
EKEric J. Kremer
Eric J. Kremer
Introduction: Human adenovirus (HAdV)-derived vectors have been used in numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV-based vaccines focuses on improving transgene immunogenicity and safety. Because pre-existing humoral immunity against HAdV types correlate with reduced vaccine efficacy and safety, many groups are exploring the development of HAdV types vectors with lower seroprevalence. However, global seroepidemiological data are incomplete. Areas covered: The goal of this review is to centralize 65 years of research on (primarily) HAdV epidemiology. After briefly addressing adenovirus biology, we chronical HAdV seroprevalence studies and highlight major milestones. Finally, we analyze data from about 50 studies with respect to HAdVs types that are currently used in the clinic, or are in the developmental pipeline. Expert opinion: Vaccination is among the most efficient tools to prevent infectious disease. HAdV-based vaccines have undeniable potential, but optimization is needed and antivector immunity remains a challenge if the same vectors are to be administrated to different populations. Here, we identify gaps in our knowledge and the need for updated worldwide epidemiological data.

1 August 2012 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
AEAndrew C. Emery
Andrew C. Emery
JDJohn O. DiRaddo
John O. DiRaddo
EMEric Miller
Eric Miller
HHHannah A. Hathaway
Hannah A. Hathaway
SPSergey Pshenichkin
Sergey Pshenichkin
JWJarda T. Wroblewski
Jarda T. Wroblewski
The metabotropic glutamate 1a (mGlu1a) receptor is a G protein-coupled receptor linked with phosphoinositide (PI) hydrolysis and with β-arrestin-1-mediated sustained extracellular signal-regulated kinase (ERK) phosphorylation and cytoprotective signaling. Previously, we reported the existence of ligand bias at this receptor, inasmuch as glutamate induced both effects, whereas quisqualate induced only PI hydrolysis. In the current study, we showed that mGlu1 receptor agonists such as glutamate, aspartate, and l-cysteate were unbiased and activated both signaling pathways, whereas quisqualate and (S)-3,5-dihydroxyphenylglycine stimulated only PI hydrolysis. Competitive antagonists inhibited only PI hydrolysis and not the β-arrestin-dependent pathway, whereas a noncompetitive mGlu1 receptor antagonist blocked both pathways. Mutational analysis of the ligand binding domain of the mGlu1a receptor revealed that Thr188 residues were essential for PI hydrolysis but not for protective signaling, whereas Arg323 and Lys409 residues were required for β-arrestin-1-mediated sustained ERK phosphorylation and cytoprotective signaling but not for PI hydrolysis. Therefore, the mechanism of ligand bias appears to involve different modes of agonist interactions with the receptor ligand binding domain. Although some mGlu1a receptor agonists are biased toward PI hydrolysis, we identified two endogenous compounds, glutaric acid and succinic acid, as new mGlu1 receptor agonists that are fully biased toward β-arrestin-mediated protective signaling. Pharmacological studies indicated that, in producing the two effects, glutamate interacted in two distinct ways with mGlu1 receptors, inasmuch as competitive mGlu1 receptor antagonists that blocked PI hydrolysis did not inhibit cytoprotective signaling. Quisqualate, which is biased toward PI hydrolysis, failed to inhibit glutamate-induced protection, and glutaric acid, which is biased toward protection, did not interfere with glutamate-induced PI hydrolysis. Taken together, these data indicate that ligand bias at mGlu1 receptors is attributable to different modes of receptor-glutamate interactions, which are differentially coupled to PI hydrolysis and β-arrestin-mediated cytoprotective signaling, and they reveal the existence of new endogenous agonists acting at mGlu1 receptors.

1 August 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
AEAndrew C. Emery
Andrew C. Emery
SPSergey Pshenichkin
Sergey Pshenichkin
GDGuy Rodrigue Takoudjou Dzomo
Guy Rodrigue Takoudjou Dzomo
EGEwa Grajkowska
Ewa Grajkowska
BWBarry B. Wolfe
Barry B. Wolfe
JWJarda T. Wroblewski
Jarda T. Wroblewski
Metabotropic glutamate receptor 1 (mGlu1) is a G protein-coupled receptor that enhances the hydrolysis of membrane phosphoinositides. In addition to its role in synaptic transmission and plasticity, mGlu1 has been shown to be involved in neuroprotection and neurodegeneration. In this capacity, we have reported previously that in neuronal cells, mGlu1a exhibits the properties of a dependence receptor, inducing apoptosis in the absence of glutamate, while promoting neuronal survival in its presence (Pshenichkin, S., Dolińska, M., Klauzińska, M., Luchenko, V., Grajkowska, E., and Wroblewski, J. T. (2008) Neuropharmacology 55, 500-508). Here, using CHO cells expressing mGlu1a receptors, we show that the protective effect of glutamate does not rely on the classical mGlu1 signal transduction. Instead, mGlu1a protective signaling is mediated by a novel, G protein-independent, pathway which involves the activation of the MAPK pathway and a sustained phosphorylation of ERK, which is distinct from the G protein-mediated transient ERK phosphorylation. Moreover, the sustained phosphorylation of ERK and protective signaling through mGlu1a receptors require expression of beta-arrestin-1, suggesting a possible role for receptor internalization in this process. Our data reveal the existence of a novel, noncanonical signaling pathway associated with mGlu1a receptors, which mediates glutamate-induced protective signaling.

1 September 2020 in Virologica Sinica
Verified
Journal Article
Closed access
PDF file
FMFranck J.D. Mennechet
Franck J.D. Mennechet
GDGuy Rodrigue Takoudjou Dzomo
Guy Rodrigue Takoudjou Dzomo

7 March 2019 in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Verified
Journal Article
Closed access
PDF file
EKEduardo Kattan
Eduardo Kattan
GDGuy Rodrigue Takoudjou Dzomo
Guy Rodrigue Takoudjou Dzomo
KVKaren Venegas
Karen Venegas
JBJulio Brousse
Julio Brousse
ADAlejandro Delfino
Alejandro Delfino
RBRodrigo Lopez Barreda
Rodrigo Lopez Barreda

7 June 2022 in medRxiv
Verified
Preprint
Open access
PDF file
AOAline Raissa Ouoba
Aline Raissa Ouoba
OPOcéane Paris
Océane Paris
CAChatté Adawaye
Chatté Adawaye
GDGuy Rodrigue Takoudjou Dzomo
Guy Rodrigue Takoudjou Dzomo
AFAbderrazzack Adoum Fouda
Abderrazzack Adoum Fouda
FMFranck J.D. Mennechet
Franck J.D. Mennechet
Vaccines derived from human adenoviruses (HAdV) are currently being used and trialed against numerous infectious agents. However, pre-existing humoral immunity can impair vaccines efficacy and safety. Strategies to circumvent this immunity often involve the use of vectors with lower seroprevalence. We evaluated HAdV-C5, HAdV-D26 and HAdV-B35 seroprevalence from healthy and HIV-infected populations from Burkina Faso and Chad. Seroprevalence for HAdV-C5 was high and comparable between countries (54%-66%), and the highest in the HIV-infected groups from sub-Saharan regions (∼90%). However, compared to France (4%), seroprevalence for HAdV-D26 was significantly higher in sub- Saharan groups (∼47%). By contrast, HAdV-B35 seroprevalence was low for all groups tested. We also found that HAdV-D26 complexed with immunoglobulins induced strong activation of dendritic cells in vitro. Our study fills gaps in the epidemiological data needed to optimize HAdV-derived vaccines in sub-Saharan regions, and highlights the necessity to better adjust vaccination strategies in Africa. Article summary line: HAdVs Seroprevalence in Burkina Faso and Chad